{"id":65206,"date":"2026-05-13T22:35:50","date_gmt":"2026-05-13T14:35:50","guid":{"rendered":"https:\/\/flcube.com\/?p=65206"},"modified":"2026-05-13T22:35:51","modified_gmt":"2026-05-13T14:35:51","slug":"bayer-reports-4-1-q1-sales-growth-to-e13-4b-with-mixed-pharmaceutical-performance-amid-ira-impact-and-generic-competition","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65206","title":{"rendered":"Bayer Reports 4.1% Q1 Sales Growth to \u20ac13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition"},"content":{"rendered":"\n<p><strong>Bayer AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/BAYN:ETR\">ETR: BAYN<\/a>) reported <strong>first-quarter 2026 group sales of \u20ac13.405 billion<\/strong> (USD 15.73 billion), representing <strong>4.1% year-over-year growth<\/strong>, while its <strong>pharmaceuticals division delivered \u20ac4.249 billion<\/strong> (USD 4.98 billion) in revenue, remaining roughly flat compared to the same period last year.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-overview\">Financial Performance Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q1 2026<\/th><th>YOY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Group Sales<\/strong><\/td><td>\u20ac13.405 billion<\/td><td>+4.1%<\/td><\/tr><tr><td><strong>Pharmaceuticals Revenue<\/strong><\/td><td>\u20ac4.249 billion<\/td><td>~Flat<\/td><\/tr><tr><td><strong>North America<\/strong><\/td><td>\u20ac1.465 billion<\/td><td>+15.2%<\/td><\/tr><tr><td><strong>Europe\/MEA<\/strong><\/td><td>\u20ac1.371 billion<\/td><td>-14.7%<\/td><\/tr><tr><td><strong>Asia-Pacific<\/strong><\/td><td>\u20ac1.170 billion<\/td><td>-1.3%<\/td><\/tr><tr><td><strong>Latin America<\/strong><\/td><td>\u20ac243 million<\/td><td>+9.5%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-product-performance-analysis\">Key Product Performance Analysis<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-growth-drivers\">Growth Drivers<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Q1 2026 Sales<\/th><th>YOY Change<\/th><th>Key Drivers<\/th><\/tr><\/thead><tbody><tr><td><strong>Nubeqa (darolutamide)<\/strong><\/td><td>\u20ac749 million<\/td><td>+57.1%<\/td><td>Sustained volume growth across all regions, particularly U.S. and Europe; slight deceleration due to U.S. Inflation Reduction Act pricing effects<\/td><\/tr><tr><td><strong>Kerendia (finerenone)<\/strong><\/td><td>\u20ac274 million<\/td><td>+84.2%<\/td><td>Substantial volume increases in U.S. and China<\/td><\/tr><tr><td><strong>Adalat (nifedipine)<\/strong><\/td><td>\u20ac171 million<\/td><td>+25.6%<\/td><td>Strong market uptake in antihypertensive segment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-declining-products\">Declining Products<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Q1 2026 Sales<\/th><th>YOY Change<\/th><th>Key Challenges<\/th><\/tr><\/thead><tbody><tr><td><strong>Eylea (aflibercept)<\/strong><\/td><td>\u20ac623 million<\/td><td>-20.5%<\/td><td>Generic erosion in Canada and Europe affecting pricing; partially offset by Eylea 8mg launch (46% of total Eylea sales)<\/td><\/tr><tr><td><strong>Aspirin (secondary MI prevention)<\/strong><\/td><td>\u20ac13\u65e5\u665a\u95f4<\/td><td>-28.5%<\/td><td>Impact from China&#8217;s volume-based procurement (VBP) tender rounds<\/td><\/tr><tr><td><strong>Stivarga (regorafenib)<\/strong><\/td><td>\u20ac76 million<\/td><td>-17.4%<\/td><td>VBP-related pricing pressure in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regional-performance-dynamics\">Regional Performance Dynamics<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-north-america-strength-15-2\">North America Strength (+15.2%)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary growth engine<\/strong> for pharmaceuticals division<\/li>\n\n\n\n<li><strong>Nubeqa momentum<\/strong> driven by strong U.S. prostate cancer market adoption<\/li>\n\n\n\n<li><strong>Kerendia expansion<\/strong> benefiting from cardiovascular risk reduction positioning<\/li>\n\n\n\n<li><strong>IRA headwinds<\/strong>: Inflation Reduction Act beginning to impact pricing, particularly for Nubeqa<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-europe-mea-weakness-14-7\">Europe\/MEA Weakness (-14.7%)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Generic competition<\/strong> significantly impacting Eylea pricing<\/li>\n\n\n\n<li><strong>Market access challenges<\/strong> across multiple therapeutic areas<\/li>\n\n\n\n<li><strong>Currency headwinds<\/strong> potentially contributing to reported decline<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-asia-pacific-stability-1-3\">Asia-Pacific Stability (-1.3%)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mixed performance<\/strong>: Kerendia showing strong China growth offset by VBP impacts on legacy products<\/li>\n\n\n\n<li><strong>China VBP effects<\/strong>: Aspirin and Stivarga facing significant pricing pressure from procurement rounds<\/li>\n\n\n\n<li><strong>Emerging market resilience<\/strong>: Partial offset from other Asia-Pacific markets<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-product-highlights\">Strategic Product Highlights<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-eylea-franchise-evolution\">Eylea Franchise Evolution<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Eylea 8mg launch success<\/strong>: New extended-dosing formulation accounts for <strong>46% of total Eylea sales<\/strong><\/li>\n\n\n\n<li><strong>Franchise defense strategy<\/strong>: Higher-concentration formulation designed to maintain market share amid biosimilar competition<\/li>\n\n\n\n<li><strong>Pricing pressure management<\/strong>: Innovation helping mitigate generic erosion impact<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-oncology-portfolio-resilience\">Oncology Portfolio Resilience<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Nubeqa leadership<\/strong>: Maintaining strong growth trajectory despite IRA-related pricing headwinds<\/li>\n\n\n\n<li><strong>Prostate cancer market expansion<\/strong>: Continued volume growth indicating sustained market penetration<\/li>\n\n\n\n<li><strong>Therapeutic area focus<\/strong>: Oncology remains key growth pillar for Bayer&#8217;s pharmaceutical strategy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-forward-outlook\">Market Context &amp; Forward Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IRA implementation<\/strong>: U.S. Inflation Reduction Act beginning to affect innovative drug pricing, with potential for increased impact in coming quarters<\/li>\n\n\n\n<li><strong>China VBP expansion<\/strong>: Volume-based procurement continuing to pressure legacy product revenues, requiring portfolio rebalancing<\/li>\n\n\n\n<li><strong>Innovation pipeline importance<\/strong>: Success of newer products (Nubeqa, Kerendia) critical to offsetting generic erosion on established brands<\/li>\n\n\n\n<li><strong>Geographic diversification<\/strong>: Regional performance disparities highlighting need for balanced global strategy<\/li>\n<\/ul>\n\n\n\n<p>The Q1 results reflect Bayer&#8217;s <strong>transition phase<\/strong>, where innovative products are driving growth while legacy assets face increasing pricing and competitive pressures across key markets.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, market dynamics, and strategic outlook. Actual results may differ due to risks including regulatory changes, competitive pressures, and macroeconomic factors.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/bayer-quarterly-statement-q1-2026.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of bayer-quarterly-statement-q1-2026.\"><\/object><a id=\"wp-block-file--media-e57c2644-18ad-4fde-8ecd-c8828774e295\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/bayer-quarterly-statement-q1-2026.pdf\">bayer-quarterly-statement-q1-2026<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/bayer-quarterly-statement-q1-2026.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e57c2644-18ad-4fde-8ecd-c8828774e295\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Bayer AG (ETR: BAYN) reported first-quarter 2026 group sales of \u20ac13.405 billion (USD 15.73 billion),&#8230;<\/p>\n","protected":false},"author":1,"featured_media":65208,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[],"class_list":["post-65206","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bayer Reports 4.1% Q1 Sales Growth to \u20ac13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bayer AG (ETR: BAYN) reported first-quarter 2026 group sales of \u20ac13.405 billion (USD 15.73 billion), representing 4.1% year-over-year growth, while its pharmaceuticals division delivered \u20ac4.249 billion (USD 4.98 billion) in revenue, remaining roughly flat compared to the same period last year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65206\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer Reports 4.1% Q1 Sales Growth to \u20ac13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition\" \/>\n<meta property=\"og:description\" content=\"Bayer AG (ETR: BAYN) reported first-quarter 2026 group sales of \u20ac13.405 billion (USD 15.73 billion), representing 4.1% year-over-year growth, while its pharmaceuticals division delivered \u20ac4.249 billion (USD 4.98 billion) in revenue, remaining roughly flat compared to the same period last year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65206\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T14:35:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-13T14:35:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1301.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65206#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65206\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer Reports 4.1% Q1 Sales Growth to \u20ac13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition\",\"datePublished\":\"2026-05-13T14:35:50+00:00\",\"dateModified\":\"2026-05-13T14:35:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65206\"},\"wordCount\":506,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65206#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1301.webp\",\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65206#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65206\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65206\",\"name\":\"Bayer Reports 4.1% Q1 Sales Growth to \u20ac13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65206#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65206#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1301.webp\",\"datePublished\":\"2026-05-13T14:35:50+00:00\",\"dateModified\":\"2026-05-13T14:35:51+00:00\",\"description\":\"Bayer AG (ETR: BAYN) reported first-quarter 2026 group sales of \u20ac13.405 billion (USD 15.73 billion), representing 4.1% year-over-year growth, while its pharmaceuticals division delivered \u20ac4.249 billion (USD 4.98 billion) in revenue, remaining roughly flat compared to the same period last year.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65206#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65206\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65206#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1301.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1301.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bayer Reports 4.1% Q1 Sales Growth to \u20ac13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65206#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer Reports 4.1% Q1 Sales Growth to \u20ac13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer Reports 4.1% Q1 Sales Growth to \u20ac13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition - Insight, China&#039;s Pharmaceutical Industry","description":"Bayer AG (ETR: BAYN) reported first-quarter 2026 group sales of \u20ac13.405 billion (USD 15.73 billion), representing 4.1% year-over-year growth, while its pharmaceuticals division delivered \u20ac4.249 billion (USD 4.98 billion) in revenue, remaining roughly flat compared to the same period last year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65206","og_locale":"en_US","og_type":"article","og_title":"Bayer Reports 4.1% Q1 Sales Growth to \u20ac13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition","og_description":"Bayer AG (ETR: BAYN) reported first-quarter 2026 group sales of \u20ac13.405 billion (USD 15.73 billion), representing 4.1% year-over-year growth, while its pharmaceuticals division delivered \u20ac4.249 billion (USD 4.98 billion) in revenue, remaining roughly flat compared to the same period last year.","og_url":"https:\/\/flcube.com\/?p=65206","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-13T14:35:50+00:00","article_modified_time":"2026-05-13T14:35:51+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1301.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65206#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65206"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer Reports 4.1% Q1 Sales Growth to \u20ac13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition","datePublished":"2026-05-13T14:35:50+00:00","dateModified":"2026-05-13T14:35:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65206"},"wordCount":506,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=65206#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1301.webp","articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65206#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65206","url":"https:\/\/flcube.com\/?p=65206","name":"Bayer Reports 4.1% Q1 Sales Growth to \u20ac13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=65206#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=65206#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1301.webp","datePublished":"2026-05-13T14:35:50+00:00","dateModified":"2026-05-13T14:35:51+00:00","description":"Bayer AG (ETR: BAYN) reported first-quarter 2026 group sales of \u20ac13.405 billion (USD 15.73 billion), representing 4.1% year-over-year growth, while its pharmaceuticals division delivered \u20ac4.249 billion (USD 4.98 billion) in revenue, remaining roughly flat compared to the same period last year.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65206#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65206"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=65206#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1301.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1301.webp","width":1080,"height":608,"caption":"Bayer Reports 4.1% Q1 Sales Growth to \u20ac13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65206#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer Reports 4.1% Q1 Sales Growth to \u20ac13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1301.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65206","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65206"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65206\/revisions"}],"predecessor-version":[{"id":65209,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65206\/revisions\/65209"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/65208"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65206"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65206"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65206"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}